List of Excipients in API ceftibuten dihydrate
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing ceftibuten dihydrate
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Sciele Pharma Inc | CEDAX | ceftibuten dihydrate | 59630-820 | BENZYL ALCOHOL | |
| Sciele Pharma Inc | CEDAX | ceftibuten dihydrate | 59630-820 | BUTYLPARABEN | |
| Sciele Pharma Inc | CEDAX | ceftibuten dihydrate | 59630-820 | EDETATE CALCIUM DISODIUM | |
| Sciele Pharma Inc | CEDAX | ceftibuten dihydrate | 59630-820 | GELATIN | |
| Sciele Pharma Inc | CEDAX | ceftibuten dihydrate | 59630-820 | METHYLPARABEN | |
| Sciele Pharma Inc | CEDAX | ceftibuten dihydrate | 59630-820 | POLYSORBATE 80 | |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for ceftibuten dihydrate
Excipient focus: BENZYL ALCOHOL
ceftibuten dihydrate drug variants containing BENZYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Sciele Pharma Inc | ceftibuten dihydrate | 59630-820 |
| >Company | >Ingredient | >NDC |
ceftibuten dihydrate drug variants not containing BENZYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: BUTYLPARABEN
ceftibuten dihydrate drug variants containing BUTYLPARABEN
| Company | Ingredient | NDC |
|---|---|---|
| Sciele Pharma Inc | ceftibuten dihydrate | 59630-820 |
| >Company | >Ingredient | >NDC |
ceftibuten dihydrate drug variants not containing BUTYLPARABEN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: EDETATE CALCIUM DISODIUM
ceftibuten dihydrate drug variants containing EDETATE CALCIUM DISODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Sciele Pharma Inc | ceftibuten dihydrate | 59630-820 |
| >Company | >Ingredient | >NDC |
ceftibuten dihydrate drug variants not containing EDETATE CALCIUM DISODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: GELATIN
ceftibuten dihydrate drug variants containing GELATIN
| Company | Ingredient | NDC |
|---|---|---|
| Sciele Pharma Inc | ceftibuten dihydrate | 59630-820 |
| >Company | >Ingredient | >NDC |
ceftibuten dihydrate drug variants not containing GELATIN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: METHYLPARABEN
ceftibuten dihydrate drug variants containing METHYLPARABEN
| Company | Ingredient | NDC |
|---|---|---|
| Sciele Pharma Inc | ceftibuten dihydrate | 59630-820 |
| >Company | >Ingredient | >NDC |
ceftibuten dihydrate drug variants not containing METHYLPARABEN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYSORBATE 80
ceftibuten dihydrate drug variants containing POLYSORBATE 80
| Company | Ingredient | NDC |
|---|---|---|
| Sciele Pharma Inc | ceftibuten dihydrate | 59630-820 |
| >Company | >Ingredient | >NDC |
ceftibuten dihydrate drug variants not containing POLYSORBATE 80
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: PROPYLPARABEN
ceftibuten dihydrate drug variants containing PROPYLPARABEN
| Company | Ingredient | NDC |
|---|---|---|
| Sciele Pharma Inc | ceftibuten dihydrate | 59630-820 |
| >Company | >Ingredient | >NDC |
ceftibuten dihydrate drug variants not containing PROPYLPARABEN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM LAURYL SULFATE
ceftibuten dihydrate drug variants containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| Sciele Pharma Inc | ceftibuten dihydrate | 59630-820 |
| >Company | >Ingredient | >NDC |
ceftibuten dihydrate drug variants not containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM PROPIONATE
ceftibuten dihydrate drug variants containing SODIUM PROPIONATE
| Company | Ingredient | NDC |
|---|---|---|
| Sciele Pharma Inc | ceftibuten dihydrate | 59630-820 |
| >Company | >Ingredient | >NDC |
ceftibuten dihydrate drug variants not containing SODIUM PROPIONATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
ceftibuten dihydrate drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Sciele Pharma Inc | ceftibuten dihydrate | 59630-820 |
| >Company | >Ingredient | >NDC |
ceftibuten dihydrate drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch